Exploring Analyst Estimates for Ionis Pharmaceuticals (IONS) Q4 Earnings, Beyond Revenue and EPS

Core Viewpoint - Ionis Pharmaceuticals is expected to report a significant quarterly loss and a substantial decline in revenues compared to the previous year [1] Financial Performance - Analysts predict a quarterly loss of $1.12 per share, reflecting a decline of 1766.7$137.47 million, representing a year-over-year decrease of 57.7% [1] Earnings Estimates Revisions - Over the last 30 days, there has been an upward revision of 3.7% in the consensus EPS estimate for the quarter [2] - Revisions to earnings estimates are crucial indicators for predicting potential investor actions regarding the stock [3] Revenue Breakdown - Revenue from Spinraza royalties is estimated to reach $60.73 million, indicating a year-over-year change of -2$5.23 million, reflecting a year-over-year change of -34.7% [5] - Total commercial revenue is estimated at $80.55 million, showing a change of +2$7.06 million, indicating a change of -21.6% from the prior-year quarter [6] - Collaborative agreement revenue is projected at $43.79 million, reflecting a year-over-year change of -75.5% [7] Market Performance - Shares of Ionis Pharmaceuticals have experienced a change of -1.2% in the past month, compared to a +4.7% move of the Zacks S&P 500 composite [7] - The company holds a Zacks Rank 3 (Hold), indicating it is expected to mirror overall market performance in the near future [7]